We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Elan Pharmaceuticals Licenses Software and Databases from Genego

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GeneGo, Inc. has announced that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore is designed for functional analysis of biological and chemistry data. Elan will use MetaCore in their neurology and autoimmune programs.

“We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research.”